# **Special Issue**

### **Advances in Neurofibromatosis**

### Message from the Guest Editors

Neurofibromatosis (NF) is a group of genetic disorders characterized by neurological and cutaneous manifestations. It includes neurofibromatosis type 1 (NF1), NF2-related schwannomatosis (previously known as neurofibromatosis type 2 or NF2), SMARCB1-and LZTR1-related schwannomatosis, and schwannomatosis without NF2, SMARCB1, and LZTR1 pathogenic variants in the blood. Recent advancements in NF research have brought new hope and improved outcomes for individuals affected by these complex genetic disorders. This Special Issue aims to showcase the latest research on NF. We invite you to share your research and insights through original research articles and reviews. Potential research areas for this Special Issue include the following:

- Molecular and genetic mechanisms underlying NF
- Novel phenotype-genotype correlations in NF
- Novel methods and recommendations for variant classification in genes associated with NF
- Innovative diagnostic techniques in NF
- Novel therapeutic targets in NF
- Novel biomarkers for NF
- Clinical trials exploring innovative therapeutic approaches for NF patients
- Guidelines for the diagnosis and management of NF

### **Guest Editors**

Dr. Yunjia Chen

Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA

Dr. Yulong Fu

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

### Deadline for manuscript submissions

30 June 2026



### Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/208727

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



### **About the Journal**

### Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

#### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

